This database is populated with information on the results of Roche-sponsored clinical trials.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: III A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients with Colon Cancer
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: IV A Study of Avastin (Bevacizumab) in Combination with Chemotherapy in Patients with Metastatic Cancer of the Colon or Rectum
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: II A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients with Metastatic Cancer of the Colon or Rectum
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: II A Study of Avastin (Bevacizumab) and Oxalplatin Plus Xeloda (Capacitabine) in Patients With Advanced Colorectal Cancer.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: II A Study of Avastin (Bevacizumab) Plus Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: III A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: III A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: II A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: III A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: II A Study of Avastin (Bevacizumab) in Patients With Newly Diagnosed Locally Advanced Rectal Cancer.
Product Name: Avastin [bevacizumab] Date of Report: 5/1/2007 Phase: IV A single arm study to assess the efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-fluorouracil/folic acid regimens as first line treatment for patients with metastatic colorectal cancer.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: IV OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: II A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: III A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients WIth Metastatic Colorectal Cancer.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: III A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients WIth Metastatic Colorectal Cancer.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: III A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
Product Name: Avastin [bevacizumab] Date of Report: To be Published Phase: II A Study of Avastin (Bevacizumab) in Combination With XELOX Patients With Metastatic Colorectal Cancer.
Product Name: Tarceva [erlotinib] Date of Report: To be Published Phase: II A Dose-Finding Study of Tarceva (Erlotinib) in Combination Chemotherapy for Metastatic Colorectal Cancer.
Product Name: Xeloda [capecitabine] Date of Report: 2/16/2004 Phase: II An Open-Label, Phase II Study of Capecitabine in Combination with Oxaliplatin as First-Line Treatment for Patients with Advanced and/or Metastatic Colorectal Cancer
Product Name: Xeloda [capecitabine] Date of Report: 3/2/2004 Phase: II An open-label Phase II study of intermittent oral capecitabine in the first-line treatment of patients with metastatic colorectal cancer
Product Name: Xeloda [capecitabine] Date of Report: 8/31/2004 Phase: III An open-label, randomized, phase III study comparing Xeloda (capecitabine) with iv bolus 5-fluorouracil in combination with low-dose leucovorin as adjuvant chemotherapy in patients who underwent surgery for Dukes C colon cancer
Product Name: Xeloda [capecitabine] Date of Report: To be Published Phase: III A Study of Capecitabine (Xeloda) Plus Oxaliplatin in Patients With Colon Cancer
Product Name: Xeloda [capecitabine] Date of Report: To be Published Phase: II A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
Product Name: Xeloda [capecitabine] Date of Report: To be Published Phase: II SOCRATES study A Study of Xeloda (Capecitabine) in Patients With Locally Advanced Rectal Cancer
Product Name: Xeloda [capecitabine] Date of Report: To be Published Phase: IV A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer
Product Name: Xeloda [capecitabine] Date of Report: To be Published Phase: II A Study of Xeloda (Capecitabine) Plus Radiotherapy in Patients With Rectal Cancer
Product Name: Xeloda [capecitabine] Date of Report: To be Published Phase: IV A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
Product Name: Xeloda [capecitabine] Date of Report: 11/1/2005 Phase: II A phase II study of oral Xeloda (capecitabine) in combination with intravenous irinotecan for patients with locally advanced and/or metastatic colorectal cancer (ROXI trial).
Product Name: Xeloda [capecitabine] Date of Report: To be Published Phase: II A Study of Xeloda (Capecitabine) Combined With Standard Radiotherapy in Patients With Locally Advanced Rectal Cancer
Product Name: Xeloda [capecitabine] Date of Report: To be Published Phase: IV A Study of Xeloda (Capecitabine) in the Adjuvant Treatment of Patients With Resected Colon Cancer
Product Name: Xeloda [capecitabine] Date of Report: 12/1/2006 Phase: III An open label multi-center trial to assess the pharmacokinetic interaction between capecitabine and oxaliplatin in patients with metastatic colorectal cancer.
Product Name: Xeloda [capecitabine] Date of Report: 2/1/2007 Phase: III 2 x 2 Factorial randomized phase III study of intermittent oral capecitabine in combination with intravenous oxaliplatin (q3w) ("XELOX") with/without intravenous bevacizumab (q3w) versus bolus and continuous infusion fluorouracil/intravenous leucovorin with intravenous oxaliplatin (q2w) ("FOLFOX-4") with/without intravenous bevacizumab (q2w) as first-line treatment for patients with metastatic colorectal cancer.
Product Name: Xeloda [capecitabine] Date of Report: 2/1/2007 Phase: III An open-label randomized phase III study of intermittent oral capcitabine in combination with intravenous oxaliplatin (Q3W) ("XELOX") versus bolus and continuous infusion fluorouracil/intravenous leucovorin with intravenous oxaliplatin (Q2W) ("FOLFOX4") as treatment for patients with metastatic colorectal cancer who have received prior treatment with irinotecan in combination with 5-FU/LV as first line therapy.
Product Name: Xeloda [capecitabine] Date of Report: To be Published Phase: IV A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
Product Name: Xeloda [capecitabine] Date of Report: 9/3/2007 Phase: II A Phase II Study of Capecitabine plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer.
Product Name: Xeloda [capecitabine] Date of Report: 9/3/2007 Phase: II An open-label phase II study of continuous oral capecitabine in combination with weekly irinotecan in patients with advanced and/or metastatic colorectal cancer.
Product Name: Xeloda [capecitabine] Date of Report: 12/12/2007 Phase: III Randomized, open-label, comparative phase III study of capecitabine plus oxaliplatin (XELOX) versus infusional 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX 6) as first-line combination chemotherapy in patients with metastatic colorectal cancer.
Product Name: Xeloda [capecitabine] Date of Report: 1/15/2008 Phase: II An open-label phase II study to analyze the efficacy and tolerability of capecitabine in metastatic colorectal cancer patients with regards to the expression profile of key enzymes in the capecitabine metabolism.
Product Name: Xeloda [capecitabine] Date of Report: To be Published Phase: II A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer.
© 1996-2008 F.Hoffmann-La Roche Ltd See our legal Statement
© 1996-2008 F.Hoffmann-La Roche Ltd See our legal Statement